---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-076214"
form_type: "8-K"
ticker: "BTAI"
cik: "0001720893"
company_name: "BioXcel Therapeutics, Inc."
filed_at: "2025-08-11T23:59:59+00:00"
generated_at: "2026-05-17T15:34:11.036070+00:00"
event_type: "debt"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# BioXcel Therapeutics raises $30.4M net, satisfies Oaktree financing covenant

## Summary
- Raised $30.4M net from Nov 2024 ($6.2M), Mar 2025 ($13.0M), and ATM ($11.2M) financings, satisfying the Oaktree Financing Covenant.
- Covenant required $29M net by Aug 15, 2025 or 30 days after SERENITY Phase 3 final readout; now satisfied.
- As of Aug 8, 2025, BioXcel had 13,709,124 shares outstanding post-exercise of all pre-funded warrants.

## SEC filing metadata
- accession: 0001104659-25-076214
- form_type: 8-K
- ticker: BTAI
- cik: 0001720893
- company_name: BioXcel Therapeutics, Inc.
- filed_at: 2025-08-11T23:59:59+00:00
- event_type: debt
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720893/000110465925076214/0001104659-25-076214-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720893/000110465925076214/tm2523144d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-076214
- JSON: https://secwatch.observer/filing/0001104659-25-076214.json
- Plain text: https://secwatch.observer/filing/0001104659-25-076214.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.